Vcanbio Cell & Gene Engineering Corp., Ltd (SHA:600645)

Market Cap	10.85B
Revenue (ttm)	1.50B
Net Income (ttm)	72.94M
Shares Out	455.90M
EPS (ttm)	0.17
PE Ratio	144.13
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,430,492
Average Volume	8,262,366
Open	24.08
Previous Close	24.16
Day's Range	23.80 - 24.09
52-Week Range	18.45 - 30.32
Beta	0.40
RSI	34.36
Earnings Date	Aug 29, 2025

About SHA:600645

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People’s Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental sub totipotent stem cells, immune cells, adipose stem cells, and dental stem cells. The company also provides genetic testing services related to non-invasive prenatal genetic testing during pregnancy, genetic testing for d...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 2,014
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600645

Financial Performance

In 2024, SHA:600645's revenue was 1.59 billion, a decrease of -0.27% compared to the previous year's 1.59 billion. Earnings were 100.35 million, a decrease of -5.73%.